WALVAX’s clinical application for freeze-dried herpes zoster virus mRNA vaccine has been accepted
September 22, 2025
Source: drugdu
103
On September 19, WALVAX(300142) announced that its subsidiaries, Beijing Watson Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi WALVAXtechnology Co., Ltd., jointly developed with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., have submitted their clinical trial application to the National Medical Products Administration and received a "Notice of Acceptance." The vaccine's primary function is to stimulate immunity against the herpes zoster virus and is intended for the prevention of shingles.
The announcement mentioned that the acceptance numbers of the vaccine application are CXSL2500804 and CXSL2500805, and the registration classification is a preventive biological product.1.2. According to relevant regulations, after an application is accepted, it must undergo a technical review by the Center for Drug Evaluation of the National Medical Products Administration and obtain approval before clinical trials can begin.
By mid-2025, WALVAX achieved revenue of 1.154 billion yuan and net profit attributable to shareholders of the parent company of 43.16 million yuan.
https://finance.eastmoney.com/a/202509193518623078.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
